Picture of Tvardi Therapeutics logo

TVRD — Tvardi Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Cara Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

* Cara Therapeutics Inc  CARA.OQ  reported a quarterly
adjusted
loss of 23 cents​​ per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -52 cents.  The mean expectation of
three analysts for the quarter was for a loss of 25 cents per
share. Wall Street expected results to range from -26 cents
to -23 cents per share.
    * Revenue fell 47.5% to $2.56 million from a year ago;
analysts
expected $1.62 million. 
    * Cara Therapeutics Inc's reported EPS for the quarter was a
loss
of 23 cents​.
    * The company reported a quarterly loss of $12.48 million.
    * Cara Therapeutics Inc shares had risen by 6.4% this
quarter and
lost 55.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 1.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "hold"

Wall Street's median 12-month price target for Cara Therapeutics
Inc is $1.01 
This summary was machine generated from LSEG data November 15 at
02:07 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.25          -0.23          Beat
 Jun. 30 2024      -0.27          -0.37          Missed
 Mar. 31 2024      -0.40          -0.56          Missed
 Dec. 31 2023      -0.41          -0.59          Missed

Recent news on Tvardi Therapeutics

See all news